Latest News

US FDA approves Xadago to treat patients with Parkinson’s disease

US FDA approves Xadago to treat patients with Parkinson’s disease

Ferrier Research Institute and BCFNZ to create new breast cancer vaccine

Victoria University of Wellington's Ferrier Research Institute and the Breast Cancer Foundation New Zealand (BCFNZ) have joined forces to create a new vaccine for breast cancer....

Ferrier Research Institute and BCFNZ to create new breast cancer vaccine

Pierre Fabre and H-Immune to develop new cancer immunotherapies

French pharmaceutical company Pierre Fabre and H-Immune have entered a strategic research partnership to develop new cancer...

Pierre Fabre and H-Immune to develop new cancer immunotherapies

CannRx and iCAN:Israel-Cannabis form JV to launch sleep cannabis formulation

CannRx Technologies and iCAN:Israel-Cannabis have announced the formation of a joint venture (JV) in a bid to market ican.sleep, the sleep cannabis formulation....

CannRx and iCAN:Israel-Cannabis form JV to launch sleep cannabis formulation

Emergent signs $100m BARDA contract to deliver BioThrax

Emergent signs $100m BARDA contract to deliver BioThrax

PCC acquires Intrathecal Therapy business from Mallinckrodt for $203m

PCC acquires Intrathecal Therapy business from Mallinckrodt for $203m

Circassia to acquire US rights to Tudorza and Duaklir from AstraZeneca for $230m

UK-based specialty biopharmaceutical company Circassia Pharmaceuticals has reached an agreement for the transformational acquisition of US commercial rights to two chronic obstructive...

Circassia to acquire US rights to Tudorza and Duaklir from AstraZeneca for $230m

NICE rejects use of daratumumab (darzalex) monotherapy for treatment of myeloma

NICE rejects use of daratumumab (darzalex) monotherapy for treatment of myeloma

Bellus Health agrees to sell Thallion to US firm Taro Pharmaceuticals

Bellus Health has signed an agreement to sell its wholly owned subsidiary Thallion Pharmaceuticals, including all the rights to the Shigamab drug candidate to US-based Taro...

Bellus Health agrees to sell Thallion to US firm Taro Pharmaceuticals

Diurnal and Clinigen to introduce patient access programme for unlicensed products in Europe

UK-based pharmaceutical company Diurnal has collaborated with Clinigen's IDIS managed access unit to introduce a patient access programme for the former's Infacort and Chronocort to...

Diurnal and Clinigen to introduce patient access programme for unlicensed products in Europe

Deals this week: Innopharmax, Aurinia Pharmaceuticals, Hainan Poly Pharm

Taiwanese pharmaceutical company Innopharmax intends to issue five million shares of its common stock in order to raise funds required for meeting its research and development expenses and...

Deals this week: Innopharmax, Aurinia Pharmaceuticals, Hainan Poly Pharm

Oxford BioDynamics joins collaboration to identify biological factors that cause RA flares

UK-based biotechnology company Oxford BioDynamics has participated in a collaboration to identify biological factors that cause disease relapses, known as flares, in patients with...

Oxford BioDynamics joins collaboration to identify biological factors that cause RA flares

UK NICE Board approves changes to drug evaluation process

UK NICE Board approves changes to drug evaluation process

Sanofi’s dupilumab receives EAMS positive scientific opinion from UK MHRA for AD

Sanofi’s dupilumab receives EAMS positive scientific opinion from UK MHRA for AD

UK NICE to deny NHS access to BMS’s blood cancer drug Opdivo

The UK’s National Institute for Health and Care Excellence (NICE) has issued a draft guidance that could deny access to Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) for National...

UK NICE to deny NHS access to BMS’s blood cancer drug Opdivo

GSK submits application to FDA for expanded indication of influenza vaccine

GSK submits application to FDA for expanded indication of influenza vaccine

Japan’s MHLW grants priority review for AbbVie’s chronic HCV treatment

Japan’s MHLW grants priority review for AbbVie’s chronic HCV treatment

Alzheimer’s Research UK report reveals doubling of dementia researchers since 2008

A new analysis conducted by dementia research charity Alzheimer’s Research UK has revealed that the number of scientists working on dementia has nearly doubled over six...

Alzheimer’s Research UK report reveals doubling of dementia researchers since 2008

Rare disease patients in UK wait average of two years for medications

A new report published by Irish biotechnology company Shire has shown that rare disease patients in England have to wait an average of two years for life-changing treatments to be funded on...

Rare disease patients in UK wait average of two years for medications

ICR study reports Hodgkin lymphoma survivors at high risk of second cancers

ICR study reports Hodgkin lymphoma survivors at high risk of second cancers

Swansea University scientists participate in study into genetics of common epilepsy

Academics from Swansea University have participated in a study designed to assess the contribution of genome-wide, ultra-rare genetic variation in common...

Swansea University scientists participate in study into genetics of common epilepsy
cachename:Newscachekey:rd-1665407042_1857678299_rd-488908060_1460672566_rd1460672566_371857150_ap1460672566_1857678299_-520784304